Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 8/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.37 |
| ▸ | PSMB9 | P28065 | 4/20 | 0.37 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21774834 | 1.00 | SMYD3 (0.49) | SMYD3PSMB8PSMB5PSMB9SMYD2 | |
| SCHEMBL30216252 | 0.80 | ALDH1A1 (0.54) | ALDH1A1DPP4 | |
| SCHEMBL21733289 | 0.80 | ALDH1A1 (0.54) | ALDH1A1DPP4 | |
| SCHEMBL21774780 | 0.78 | SMYD3 (0.51) | SMYD3PSMB8PSMB5PSMB9SMYD2 | |
| SCHEMBL17592034 | 0.78 | SMYD3 (0.78) | SMYD3PSMB8PSMB5PSMB9SMYD2 | |
| SCHEMBL17592032 | 0.78 | SMYD3 (0.78) | SMYD3PSMB8PSMB5PSMB9SMYD2 | |
| SCHEMBL21774782 | 0.78 | SMYD3 (0.51) | SMYD3PSMB8PSMB5PSMB9SMYD2 | |
| SCHEMBL21774861 | 0.77 | SMYD3 (0.50) | SMYD3PSMB8PSMB5PSMB9SMYD2 | |
| SCHEMBL21774864 | 0.77 | SMYD3 (0.50) | SMYD3PSMB8PSMB5PSMB9SMYD2 | |
| SCHEMBL21733292 | 0.75 | SMYD3 (0.47) | SMYD3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20200071333-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | CYP11B2, CYP11B1, DHPS | SMYD3 4569/4885PSMB8 3483/4885PSMB5 876/4885 |
| US-20200071333-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | CYP11B2, CYP11B1, DHPS | SMYD3 4569/4885PSMB8 3483/4885PSMB5 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.